ProMedix awarded $255,000 Phase 1 STTR (nondilutive grant) from the National Science Foundation. Biz Oregon awards matching grant to support ongoing R&D and technology improvements for patient care.
After three previous meetings with regulators, ProMedix completes q-sub meeting with FDA; receiving guidance on next steps for completing design validation and safety testing in order to file for 510(k) clearance. FDA approves clinical validation of PeriFRL technology.
ProMedix was competitively selected to participate in the Creative Destruction Lab (CDL). CDL is a global startup program for seed-stage, science-based companies.
CDL-Vancouver (formerly known as CDL-West) is located in Vancouver, BC at the Sauder School of Business, University of British Columbia. Vancouver is a fast-growing tech hub on the West Coast, combining a Silicon Valley time zone with an Asia-facing outlook. CDL-Vancouver focuses on the convergence of technologies that improve human health and wellness.
ProMedix was competitively selected to receive additional capital investment directly from Baxter’s Innovation Fund and Edward Elmhurst Driven Healthcare Ventures.
The Journal of Intensive Care Medicine has accepted a manuscript comparing the FlowSense device measurements to manual waveform evaluation. It shows that the device provides accurate, repeatable results that match those of the engineer's manual waveform values.
The American Journal of Emergency medicine has accepted a manuscript detailing the effect of skin tone on CRT measurement using the FlowSense device. The paper shows that the device provides accurate measurements on patients of all skin tones and ethnicities.
ProMedix has published a review focused on the methods used at the bedside to diagnose sepsis. The focus is centered on comparing CRT versus invasive testing for sepsis diagnosis and highlights the fact that sepsis detection will require multivariable inputs.
ProMedix was accepted as a member of the first MedTech chohort in the competitive mHUB incubation accelerator.
ProMedix has published a manuscript showing that our new point-of-care technology bodes great promise for improving peripheral perfusion assessment. It also investigates the use of the device at the bedside in the emergency department triage area and during active resuscitation.
ProMedix has received a notice of allowance for our first filed patent (application number 15/405412), where Dr. Steve Baker, Dr. Matthew Hansen and Dr. David Sheridan are all co-inventors. This patent was developed in a cooperative agreement between OHSU and HillRom (now owned by Baxter), and is exclusively licensed to ProMedix, Inc.
Promedix has launched a propsective observational study in the ER. Patients will have capillary refill measurements taken with our device in triage and during their resuscitation. The primary objective is to evaluate the ability of our device to improve early sepsis detection.
ProMedix presented at the highly competitive/peer-reviewed American Heart Association Resuscitation Science Symposium
CTIP, Consortium for Technology and Innovation in Pediatrics, an FDA pediatric device consortium received over 90 applications to their grant competition. Promedix was selected as a winner due to it's ability to improve pediatric sepsis care.
Promedix launched a clinical trial in the adult ICU and inpatient floors to validate their technology in sepsis resuscitation.
Promedix presented research findings at the highly competitive Pediatric Academic Society national meeting.
Promedix received an investment from Ideaship LLC to strategically develop their patent portfolio strategy. Ideaship serves as a trusted advisor as well.
Promedix was an awardee of the highly competitive $100,000 Business Oregon Innovation Grant.